05Jul 2023
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020

Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020

A recent study from the Center for Kidney Disease Research evaluated the prescribing rates of Guideline‐Directed Medical Therapy (GDMT) in patients with diabetes and chronic kidney disease (CKD). The research analyzed data from over 39,000 adults and found that GDMT prescription rates were disappointingly low. ACE inhibitor/ARB had a baseline prescription rate of 70.7% and 40.4% at ≥90 days, SGLT2 inhibitors had 6.0% and 5.0%, while GLP‐1 receptor agonists had 6.8% and 6.3%, respectively. Patients without primary commercial health insurance coverage were less likely to receive GDMT. The study highlights the need for improved prescribing practices for better clinical outcomes.

  • #endo-diabetology

Like

Save

Share